시장보고서
상품코드
1280756

CIN 및 HR-HPV 치료 시장 예측(-2028년) - 질병 유형, 균주 유형, 제공, 제품 유형 및 최종 사용자별 분석

CIN & HR-HPV Treatment Market Forecast to 2028 - Global Analysis By Disease Type, Strain Type, Offering, Product Type, and End User

발행일: | 리서치사: The Insight Partners | 페이지 정보: 영문 245 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

CIN-HR-HPV 치료제 시장 규모는 2022년 116억 3,517만 달러, 2028년에는 171억 6,461만 달러에 달할 것으로 예상되며, 2023년부터 2028년까지 6.7%의 CAGR을 나타낼 것으로 추정됩니다.

인간유두종바이러스 감염률 증가와 자궁경부암 예방에 대한 관심이 높아지면서 시장 성장의 배경이 되고 있습니다. 그러나 재발률 증가와 CIN-HR-HPV 치료의 높은 비용이 시장 성장의 걸림돌로 작용하고 있습니다.

고위험형 인유두종 바이러스(HR-HPV)는 자궁경부 상피내종양(CIN)과 관련이 있으며, HR-HPV의 지속적인 감염은 침습성 자궁경부암을 유발합니다. 또한 HR-HPV의 아형, 특히 HPV16과 HPV18은 자궁경부암을 유발하는 것으로 알려져 있습니다. 자궁경부 상피내 신 생물의 비정상적인 세포는 악성이 아닙니다. 그러나 치료가 필요한 특정 상황에서 감시와 치료를 하지 않으면 전암이나 암으로 발전할 수 있습니다. 이러한 질병에 대한 적절한 치료는 적시에 회복하는 데 도움이 될 수 있습니다.

헬스케어 시장의 각 회사는 HPV 진단을 위한 첨단 검사를 도입하기 위해 다양한 연구 개발을 진행하고 있으며, 2021년 5월, 의료 기술 선도 기업인 BD는 가정에서 채취한 자가 질 샘플을 통해 HPV를 검사할 수 있는 첫 번째 CE 마크가 부착된 검사를 발표했습니다. 이를 통해 실험실은 BD On-Clarity HPV Assay를 사용하여 BD 희석 튜브를 통해 자가 채취한 샘플을 처리할 수 있습니다. 자가 검체 채취는 정기적인 자궁경부암 검진을 받지 않는 여성에게 접근하는 공중보건의 시급한 과제에 대응하는 데 도움이 될 수 있습니다.

2020년 9월, F. Hoffmann-La Roche는 자궁경부암 검진 결과 HR-HPV 양성인 여성을 위한 최초의 바이오마커 기반 선별검사 CINtec PLUS Cytology를 미국 식품의약국(FDA)으로부터 승인받았습니다. Cytology는 HPV 감염과 관련이 있고, 치료 시기를 놓치면 전암이나 암으로 진행될 수 있는 두 가지 바이오마커 p16과 Ki-67이 한 세포 내에 동시에 존재하는지 확인하는 검사다. 이 두 가지 바이오마커가 양성인 여성은 HR-HPV에 걸릴 위험이 더 높습니다.2022년 6월, F. Hoffmann-La Roche는 CE 마크가 승인된 국가에서 HPV 셀프 샘플링 솔루션을 출시했습니다. 이 새로운 솔루션을 통해 환자는 의료 시설에서 의료진의 지시에 따라 개인적으로 HPV 샘플을 채취할 수 있습니다. 로슈의 cobas HPV 테스트는 임상적으로 검증된 질 샘플을 분석하는 데 사용됩니다.

2021년 11월, 홀로직은 유럽에서 자궁경부암 검진용 'Genius Digital Diagnostics System'을 출시했습니다. 2021년 11월, BD의 COR PX/GX 시스템은 미국 FDA로부터 제품화 승인을 받았으며, 이 차세대 검진 시스템은 딥러닝 기반 인공지능(AI)과 최신 체적 영상 기술을 결합하여 여성의 전암 병변과 자궁경부암 세포를 평가합니다. 이 시스템은 2019년부터 유럽 전역의 중앙집중형 실험실에서 사용되어 전체 효율을 높인 대량 처리를 지원하고 있습니다. 이번 신제품 출시로 CIN-HR-HPV 치료 시장의 기업들은 지리적 범위를 확장하고 기존 고객 기반보다 더 큰 고객 기반에 대응할 수 있는 역량을 강화할 수 있을 것으로 기대됩니다.

제품 기반 인사이트

CIN-HR-HPV 치료 시장은 제공 방법에 따라 진단 방법과 치료 방법으로 분류되며, 2022년에는 치료 방법이 시장에서 더 큰 점유율을 차지할 것으로 예상됩니다. 그러나 진단 방법 부문은 예측 기간 동안 더 높은 CAGR을 나타낼 것으로 예상됩니다. 또한, 진단 방법 부문은 HPV 검사, 자궁 경부 세포진 검사, 자궁 경부 세포진 검사, 자궁 경부 세포진 검사, 생검으로 분류되며, 2022년 진단 방법 부문 시장에서 HPV 검사 부문이 가장 큰 점유율을 차지할 것으로 예상됩니다. HPV 감염에는 피부형과 점막형 두 가지 유형의 HPV 감염이 있습니다. 피부형 HPV는 팔, 가슴, 손, 발의 피부에 사마귀를 만들지만 생식기 사마귀는 포함되지 않습니다. 점막형 HPV는 점막의 세포에 감염되어 생활하는 유형입니다. 항문과 생식기에 감염되는 경우가 많기 때문에 점막형 HPV는 생식기형(또는 항문형) HPV라고도 불립니다. 이 유형은 입과 목의 점막에도 감염될 수 있습니다. 점막형 HPV는 일반적으로 피부나 다른 신체 부위에는 영향을 미치지 않는다. 또한 사마귀를 유발하고 암으로 발전할 가능성이 거의 없는 저위험 점막 HPV와 일부 암 발병과 관련된 고위험 점막 HPV로 나뉘며, HPV 검사는 자궁경부 전암과 암을 유발하기 쉬운 고위험 점막 HPV에 의한 자궁경부 감염을 감지하기 위해 시행됩니다. 검사합니다. 미국암학회는 25세에서 65세 사이의 자궁경부암 및 전암을 선별하기 위해 HPV 검사를 1차적으로 권장하고 있습니다. 또한, HPV 검사 기술에서 가정 내 검사 및 현장 검사 등의 옵션이 제공됨에 따라 HPV 검사는 PAP 스미어보다 우선순위가 높아지고 있습니다.

2023년 3월, 국제암연구소(IARC)는 의료진이 자궁경부암 검진 및 HPV 양성 사례 관리를 위해 HPV 검사를 시행하는 데 도움이 되도록 설계된 실용적인 온라인 가이드인 새로운 IARC 아틀라스를 발표했습니다.2022년 9월, Mylab Discovery Solutions는 개인의 HR-HPV를 검출하는 실시간 PCR 기반 스크리닝 솔루션인 PathoDetect HPV Detection Test의 출시를 발표했습니다. 이 검사는 대부분의 자궁경부암 환자의 원인이 되는 HPV 16주와 HPV 18주의 존재를 구분하여 검출합니다.

세계보건기구(WHO), 미국 식품의약국(FDA), 국민건강보험기금(NHIF), 인도 산부인과 의사 연맹(FOGSI) 등은 CIN-HR-HPV 치료 시장에 대한 보고서를 작성할 때 참조한 1차 및 2차 정보 중 일부입니다.

목차

제1장 서론

제2장 CIN 및 HR-HPV 치료 시장 - 중요 포인트

제3장 조사 방법

  • 조사 범위
  • 2차 조사
  • 1차 조사

제4장 CIN 및 HR-HPV 치료 시장 - 시장 구도

  • PEST 분석
    • 북미의 PEST 분석
    • 유럽의 PEST 분석
    • 아시아태평양의 PEST 분석
    • 중남미의 PEST 분석
    • 중동 및 아프리카의 PEST 분석
  • 전문가의 견해

제5장 CIN 및 HR-HPV 치료 시장 - 주요 시장 역학

  • 시장 성장 촉진요인
    • 인유두종바이러스 감염증 유병률 증가
    • 자궁경부암 예방을 위한 적극적인 대처
  • 시장 성장 억제요인
    • CIN 및 HR-HPV 치료의 재발율 상승과 고비용
  • 시장 기회
    • 혁신적인 제품 개발 및 출시
  • 향후 동향
    • CIN 및 HR-HPV 스크리닝과 진단 최신 기술 사용
  • 영향 분석

제6장 CIN 및 HR-HPV 치료 시장 - 세계 분석

  • 세계의 CIN 및 HR-HPV 치료 시장 매출과 예측·분석
  • 세계의 CIN 및 HR-HPV 치료 시장 : 지역별 예측·분석
  • 주요 기업의 시장 포지셔닝

제7장 세계의 CIN 및 HR-HPV 치료 시장 매출과 예측(-2028년) - 질환 유형별

  • 세계의 CIN 및 HR-HPV 치료 시장, 질환 유형별, 2022년·2028년(%)
  • CIN 1
  • CIN 2
  • CIN 3

제8장 세계의 CIN 및 HR-HPV 치료 시장 매출과 예측(-2028년) - 균주 유형별

  • 세계의 CIN 및 HR-HPV 치료 시장, 균주 유형별, 2022년·2028년(%)
  • HPV 16
  • HPV 18
  • 기타

제9장 세계의 CIN 및 HR-HPV 치료 시장 매출과 예측(-2028년) - 제공별

  • 세계의 CIN 및 HR-HPV 치료 시장, 제공별, 2022년·2028년(%)
  • 진단
  • 치료

제10장 세계의 CIN 및 HR-HPV 치료 시장 분석·2028년 예측-제품 유형별

  • 세계의 CIN 및 HR-HPV 치료 시장 : 제품 유형별, 2022년·2028년(%)
  • 키트 및 시약
  • 기기
  • 서비스

제11장 세계의 CIN 및 HR-HPV 치료 시장 분석·2028년 예측 : 최종사용자별

  • 세계의 CIN 및 HR-HPV 치료 시장 : 최종사용자별, 2022년·2028년(%)
  • 병원 및 진료소
  • 진단실험실
  • 전문 임상 기관
  • 기타

제12장 CIN 및 HR-HPV 치료 시장 매출과 예측(-2028년) - 지역별 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 개요
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 개요
      • 중국
      • 일본
      • 인도
      • 한국
      • 호주
      • 기타 아시아태평양
  • 중동 및 아프리카
    • 개요
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카공화국
      • 기타 중동 및 아프리카
  • 중남미
      • 아르헨티나
      • 브라질
      • 기타 중남미

제13장 COVID-19 팬데믹이 CIN 및 HR-HPV 치료 시장에 미치는 영향

  • 북미
  • 유럽
  • 아시아태평양
  • 중동 및 아프리카
  • COVID-19 팬데믹이 중남미 CIN 및 HR-HPV 치료 시장에 미치는 영향 분석

제14장 CIN 및 HR-HPV 치료 시장 - 산업 전망

  • 개요
  • CIN 및 HR-HPV 치료 시장 성장 전략
  • 유기적인 성장 전략
    • 개요
  • 무기적인 성장 전략
    • 개요

제15장 기업 개요

  • Fujirebio Europe NV
  • Qiagen NV
  • Zilico Ltd
  • Abbott Laboratories
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • INOVIO Pharmaceuticals Inc
  • Bioneer Corp
  • Antiva Biosciences Inc
  • Thermo Fisher Scientific Inc
LSH 23.06.15

The CIN & HR-HPV treatment market size was US$ 11,635.17 million in 2022, and it is projected to reach US$ 17,164.61 million by 2028; the market is estimated to record a CAGR of 6.7% from 2023 to 2028.

The market growth is attributed to an increase in the prevalence of human papillomavirus infections and favorable initiatives for preventing cervical cancer. However, the increased reoccurrence rate and the high cost of CIN & HR-HPV treatment hamper the growth of the market.

High-risk human papillomavirus (HR-HPV) is associated with cervical intraepithelial neoplasia (CIN). Persistent infection with HR-HPV results in invasive cervical cancer. Also, HR-HPV subtypes, particularly HPV 16 and HPV 18, are known to cause cervical cancer. Aberrant cells in cervical intraepithelial neoplasia aren't malignant. However, they can grow into precancer or cancer cases if not monitored or treated in certain circumstances that require therapy. Proper treatment for such disorders helps in timely recovery.

Companies in the healthcare market are undertaking various research and development activities to introduce advanced tests for HPV diagnosis. In May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples through a BD diluent tube using BD Onclarity HPV assay. The at-home collection of samples helps address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening.

In September 2020, F. Hoffmann-La Roche Ltd received the US Food and Drug Administration (FDA) approval for CINtec PLUS Cytology, the first biomarker-based triage test for women whose cervical cancer screening results are positive for HR-HPV. The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers-p16 and Ki-67-in a single cell, which is associated with HPV infections that progress to precancer or cancer if not treated on time. Women that are tested positive for these two biomarkers are more significantly at risk of HR-HPV. In June 2022, F. Hoffmann-La Roche Ltd launched HPV self-sampling solution in countries accepting the CE mark. By using this new solution, patients can collect their HPV samples privately at a healthcare facility, following instructions provided by healthcare workers. Roche's cobas HPV test is used to analyze a clinically validated vaginal sample.

In November 2021, Hologic, Inc. launched the Genius Digital Diagnostics System in Europe for cervical cancer screening. This next-generation screening system combines deep learning-based artificial intelligence (AI) with the latest volumetric imaging technology to assess precancerous lesions and cervical cancer cells in women. In November 2021, BD's COR PX/GX System won approval from the FDA for its commercialization in the US. The system has been in use in centralized labs across Europe since 2019 to aid in high-volume processing with increased overall efficiency. The launch of new products is likely to allow companies in the CIN & HR-HPV treatment market to expand their geographic reach and enhance their capacities to cater to a greater than existing customer base.

Offering-Based Insights

Based on offering, the CIN & HR-HPV treatment market is categorized into diagnostic method and treatment. In 2022, the treatment segment held a larger share of the market. However, the diagnostic method segment is expected to register a higher CAGR during the forecast period. Further, the diagnostic method segment is categorized into HPV testing, Pap smear test, colposcopy, and biopsy. The HPV testing segment held the largest share of the market for the diagnostic method segment in 2022. HPV is a group of more than 150 related viruses, some of which can cause cancer of the cervix, vagina, vulva, and other parts. HPV infections are of two types: cutaneous and mucosal. Cutaneous HPVs cause warts on the skin of arms, chest, hands, and feet; these don't include genital warts. Mucosal HPV types infect and live in mucosal cells. As they often affect the anal and genital areas, mucosal HPVs are also known as genital (or anogenital) HPVs. This type can also infect mouth and throat linings. Mucosal HPVs generally don't affect the skin or other body parts. They are further classified into low-risk mucosal HPVs that cause warts and rarely lead to cancer and high-risk mucosal HPVs associated with developing certain types of cancer. HPV testing is performed for detecting cervical infection caused by high-risk mucosal HPV types that tend to cause the precancer and cancer of the cervix. The American Cancer Society recommends HPV testing as a preferred primary method to screen for cervical cancers or precancers in individuals aged 25-65. Moreover, HPV testing is gaining preference over the PAP smear as HPV testing techniques offer options such as at-home tests and point-of-care tests.

In March 2023, the International Agency for Research on Cancer (IARC) launched a new IARC atlas, a practical online guide designed to help healthcare professionals to perform HPV tests for screening women for cervical cancer and managing HPV-positive cases. In September 2022, Mylab Discovery Solutions announced the launch of the PathoDetect HPV Detection Test, a real-time PCR-based screening solution to detect HR-HPV in individuals. This test detects the presence of HPV 16 and HPV 18 strains, which cause most cervical cancer cases, along with distinguishing among them.

The World Health Organization (WHO), US Food and Drug Administration (FDA), National Health Insurance Fund (NHIF), and Federation of Obstetricians and Gynaecologists of India (FOGSI) are among the primary and secondary sources referred to while preparing the report on the CIN & HR-HPV treatment market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the CIN & HR-HPV treatment market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the CIN & HR-HPV treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global CIN & HR-HPV Treatment Market - by Disease Type
    • 1.3.2 Global CIN & HR-HPV Treatment Market - by Strain Type
    • 1.3.3 Global CIN & HR-HPV Treatment Market - by Offering
    • 1.3.4 Global CIN & HR-HPV Treatment Market - by Product Type
    • 1.3.5 Global CIN & HR-HPV Treatment Market - by End User
    • 1.3.6 Global CIN & HR-HPV Treatment Market - by Geography

2. CIN & HR-HPV Treatment Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. CIN & HR-HPV Treatment Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific PEST Analysis
    • 4.2.4 South & Central America PEST Analysis
    • 4.2.5 Middle East & Africa PEST Analysis
  • 4.3 Expert's Opinion

5. CIN & HR-HPV Treatment Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Prevalence of Human Papillomavirus Infections
    • 5.1.2 Favorable Initiatives for Preventing Cervical Cancer
  • 5.2 Market Restraints
    • 5.2.1 Increased Reoccurrence Rate and High Cost of CIN & HR-HPV Treatment
  • 5.3 Market Opportunities
    • 5.3.1 Development and Launch of Innovative Products
  • 5.4 Future Trends
    • 5.4.1 Use of Modern Technologies in CIN & HR-HPV Screening and Diagnosis
  • 5.5 Impact Analysis

6. CIN & HR-HPV Treatment Market - Global Analysis

  • 6.1 Global CIN & HR-HPV Treatment Market Revenue Forecast and Analysis
  • 6.2 Global CIN & HR-HPV Treatment Market , by Geography - Forecast and Analysis
  • 6.3 Market Positioning of Key Players

7. Global CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028- by Disease Type

  • 7.1 Overview
  • 7.2 Global CIN and HR-HPV Treatment Market, By disease type, 2022 & 2028 (%)
  • 7.3 CIN 1
    • 7.3.1 Overview
    • 7.3.2 CIN 1: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
  • 7.4 CIN 2
    • 7.4.1 Overview
    • 7.4.2 CIN 2: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
  • 7.5 CIN 3
    • 7.5.1 Overview
    • 7.5.2 CIN 3: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)

8. Global CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028- by Strain Type

  • 8.1 Overview
  • 8.2 Global CIN and HR-HPV Treatment Market, By Strain Type, 2022 & 2028 (%)
  • 8.4 HPV 16
    • 8.4.1 Overview
    • 8.4.2 HPV 16: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
  • 8.5 HPV 18
    • 8.5.1 Overview
    • 8.5.2 HPV 18: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)

9. Global CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028- by Offering

  • 9.1 Overview
  • 9.2 Global CIN and HR-HPV Treatment Market, By Offering, 2022 & 2028 (%)
  • 9.4 Diagnostic Method
    • 9.4.1 Overview
    • 9.4.2 Diagnostic Method: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    • 9.4.3 Pap Smear
      • 9.4.3.1 Overview
      • 9.4.3.2 Pap Smear: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    • 9.4.4 HPV Testing
      • 9.4.4.1 Overview
      • 9.4.4.2 HPV Testing: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    • 9.4.5 Colposcopy
      • 9.4.5.1 Overview
      • 9.4.5.2 Colposcopy: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    • 9.4.6 Biopsy
      • 9.4.6.1 Overview
      • 9.4.6.2 Biopsy: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
  • 9.5 Treatment
    • 9.5.1 Overview
    • 9.5.2 Treatment: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
      • 9.5.2.1 Excision Surgery
        • 9.5.2.1.1 Overview
        • 9.5.2.1.2 Excision Surgery: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
      • 9.5.2.2 Ablation Techniques
        • 9.5.2.2.1 Overview
        • 9.5.2.2.2 Ablation Techniques: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)

10. Global CIN & HR-HPV Treatment Market Analysis and Forecast to 2028 - by Product Type

  • 10.1 Overview
  • 10.2 Global CIN & HR-HPV Treatment Market, by Product Type 2022 & 2028 (%)
  • 10.3 Kits & Reagents
    • 10.3.1 Overview
    • 10.3.2 Kits & Reagents: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Instrument
    • 10.4.1 Overview
    • 10.4.2 Instrument: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Services
    • 10.5.1 Overview
    • 10.5.2 Services: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)

11. Global CIN & HR-HPV Treatment Market Analysis and Forecast to 2028 - by End User

  • 11.1 Overview
  • 11.2 Global CIN & HR-HPV Treatment Market, by End User 2022 & 2028 (%)
  • 11.3 Hospital & Clinics
    • 11.3.1 Overview
    • 11.3.2 Hospital & Clinics: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • 11.4 Diagnostic Laboratories
    • 11.4.1 Overview
    • 11.4.2 Diagnostic Laboratories: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • 11.5 Specialized Clinical Laboratories
    • 11.5.1 Overview
    • 11.5.2 Specialized Clinical Laboratories: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • 11.6 Others
    • 11.6.1 Overview
    • 11.6.2 Others: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)

12. CIN & HR-HPV Treatment Market Revenue and Forecasts to 2028 - Geographical Analysis

  • 12.1 North America: CIN & HR-HPV Treatment Market
    • 12.1.1 Overview
    • 12.1.2 North America: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.1.3 North America: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)
    • 12.1.4 North America: CIN & HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)
    • 12.1.5 North America: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)
      • 12.1.5.1 North America: CIN & HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)
      • 12.1.5.2 North America: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)
    • 12.1.6 North America: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)
    • 12.1.7 North America: CIN & HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)
    • 12.1.8 North America: CIN & HR-HPV Treatment Market, by Country, 2022 & 2028 (%)
      • 12.1.8.1 US: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.8.1.1 Overview
        • 12.1.8.1.2 US: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.8.1.3 US: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)
        • 12.1.8.1.4 US: CIN & HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)
        • 12.1.8.1.5 US: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)
        • 12.1.8.1.5.1 US: CIN & HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)
        • 12.1.8.1.5.2 US: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)
        • 12.1.8.1.6 US: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)
        • 12.1.8.1.7 US: CIN & HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)
      • 12.1.8.2 Canada: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.8.2.1 Overview
        • 12.1.8.2.2 Canada: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.8.2.3 Canada: CIN & HR-HPV Treatment Market, by Type, 2019-2028 (US$ Million)0
        • 12.1.8.2.4 Canada: CIN & HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)0
        • 12.1.8.2.5 Canada: CIN & HR-HPV Treatment Market, by Offerings , 2019-2028 (US$ Million)0
        • 12.1.8.2.5.1 Canada: CIN & HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)1
        • 12.1.8.2.5.2 Canada: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)1
        • 12.1.8.2.6 Canada: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)1
        • 12.1.8.2.7 Canada: CIN & HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)2
      • 12.1.8.3 Mexico: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)3
        • 12.1.8.3.1 Overview3
        • 12.1.8.3.2 Mexico: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)3
        • 12.1.8.3.3 Mexico: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)4
        • 12.1.8.3.4 Mexico: CIN & HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)4
        • 12.1.8.3.5 Mexico: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)4
        • 12.1.8.3.5.1 Mexico: CIN & HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)5
        • 12.1.8.3.5.2 Mexico: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)5
        • 12.1.8.3.6 Mexico: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)5
        • 12.1.8.3.7 Mexico: CIN & HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)6
  • 12.2 Europe: CIN & HR-HPV Treatment Market7
    • 12.2.1 Overview7
    • 12.2.2 Europe: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)8
    • 12.2.3 Europe: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)8
    • 12.2.4 Europe: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)9
    • 12.2.5 Europe: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)9
      • 12.2.5.1 Europe: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)9
      • 12.2.5.2 Europe: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)0
    • 12.2.6 Europe: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)0
    • 12.2.7 Europe: CIN & HR-HPV Treatment Market, by End Users - Revenue and Forecast to 2028 (US$ Million)0
    • 12.2.8 Europe: CIN & HR-HPV Treatment Market, by Country, 2022 & 2028 (%)1
      • 12.2.8.1 Germany: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.1.1 Overview1
        • 12.2.8.1.2 Germany: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.1.3 Germany: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)2
        • 12.2.8.1.4 Germany: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)2
        • 12.2.8.1.5 Germany: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.1.5.1 Germany: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.1.5.2 Germany: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.1.6 Germany: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)4
        • 12.2.8.1.7 Germany: CIN & HR-HPV Treatment Market, by End Users - Revenue and Forecast to 2028 (US$ Million)4
      • 12.2.8.2 France: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.2.8.2.1 Overview5
        • 12.2.8.2.2 France: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)6
        • 12.2.8.2.3 France: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)6
        • 12.2.8.2.4 France: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)7
        • 12.2.8.2.5 France: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)7
        • 12.2.8.2.5.1 France: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)7
        • 12.2.8.2.5.2 France: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)8
        • 12.2.8.2.6 France: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)8
        • 12.2.8.2.7 France: CIN & HR-HPV Treatment Market, by End Users - Revenue and Forecast to 2028 (US$ Million)8
      • 12.2.8.3 UK: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.2.8.3.1 Overview9
        • 12.2.8.3.2 UK: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)0
        • 12.2.8.3.3 UK: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)0
        • 12.2.8.3.4 UK: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.3.5 UK: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.3.5.1 UK: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.3.5.2 UK: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)2
        • 12.2.8.3.6 UK: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)2
        • 12.2.8.3.7 UK: CIN & HR-HPV Treatment Market, by End Users - Revenue and Forecast to 2028 (US$ Million)2
      • 12.2.8.4 Italy: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.4.1 Overview3
        • 12.2.8.4.2 Italy: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)4
        • 12.2.8.4.3 Italy: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)4
        • 12.2.8.4.4 Italy: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)5
        • 12.2.8.4.5 Italy: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)5
        • 12.2.8.4.5.1 Italy: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)5
        • 12.2.8.4.5.2 Italy: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)6
        • 12.2.8.4.6 Italy: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)6
        • 12.2.8.4.7 Italy: CIN & HR-HPV Treatment Market, by End Users - Revenue and Forecast to 2028 (US$ Million)6
      • 12.2.8.5 Spain: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.2.8.5.1 Overview7
        • 12.2.8.5.2 Spain: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.2.8.5.3 Spain: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)8
        • 12.2.8.5.4 Spain: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)8
        • 12.2.8.5.5 Spain: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)8
        • 12.2.8.5.5.1 Spain: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)9
        • 12.2.8.5.5.2 Spain: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)9
        • 12.2.8.5.6 Spain: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)9
        • 12.2.8.5.7 Spain: CIN & HR-HPV Treatment Market, by End User- Revenue and Forecast to 2028 (US$ Million)0
      • 12.2.8.6 Rest of Europe: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.6.1 Overview1
        • 12.2.8.6.2 Rest of Europe: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.6.3 Rest of Europe: CIN & HR-HPV Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)1
        • 12.2.8.6.4 Rest of Europe: CIN & HR-HPV Treatment Market, by Strain Type - Revenue and Forecast to 2028 (US$ Million)2
        • 12.2.8.6.5 Rest of Europe: CIN & HR-HPV Treatment Market, by Offerings - Revenue and Forecast to 2028 (US$ Million)2
        • 12.2.8.6.5.1 Rest of Europe: CIN & HR-HPV Treatment Market, by Diagnostic Methods - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.6.5.2 Rest of Europe: CIN & HR-HPV Treatment Market, by Treatments - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.6.6 Rest of Europe: CIN & HR-HPV Treatment Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)3
        • 12.2.8.6.7 Rest of Europe: CIN & HR-HPV Treatment Market, by End Users - Revenue and Forecast to 2028 (US$ Million)4
  • 12.3 Asia Pacific: CIN & HR-HPV Treatment Market5
    • 12.3.1 Overview5
    • 12.3.2 Asia Pacific: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)6
    • 12.3.3 Asia Pacific: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)6
    • 12.3.4 Asia Pacific: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)7
    • 12.3.5 Asia Pacific: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)7
      • 12.3.5.1 Asia Pacific: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)7
      • 12.3.5.2 Asia Pacific: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)8
    • 12.3.6 Asia Pacific: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)8
    • 12.3.7 Asia Pacific: CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)8
    • 12.3.8 Asia Pacific: CIN & HR-HPV Treatment Market, by Country, 2022 & 2028 (%)9
      • 12.3.8.1 China: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.3.8.1.1 Overview9
        • 12.3.8.1.2 China: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.3.8.1.3 China: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)0
        • 12.3.8.1.4 China: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)0
        • 12.3.8.1.5 China: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)1
        • 12.3.8.1.5.1 China: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)1
        • 12.3.8.1.5.2 China: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)1
        • 12.3.8.1.6 China: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)2
        • 12.3.8.1.7 China CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)2
      • 12.3.8.2 Japan: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)3
        • 12.3.8.2.1 Overview3
        • 12.3.8.2.2 Japan: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)3
        • 12.3.8.2.3 Japan: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)4
        • 12.3.8.2.4 Japan: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)4
        • 12.3.8.2.5 Japan: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)5
        • 12.3.8.2.5.1 Japan: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)5
        • 12.3.8.2.5.2 Japan: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)5
        • 12.3.8.2.6 Japan: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)6
        • 12.3.8.2.7 Japan: CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)6
      • 12.3.8.3 India: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.3.8.3.1 Overview7
        • 12.3.8.3.2 India: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.3.8.3.3 India: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)8
        • 12.3.8.3.4 India: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)8
        • 12.3.8.3.5 India: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)8
        • 12.3.8.3.5.1 India: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)9
        • 12.3.8.3.5.2 India: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)9
        • 12.3.8.3.6 India: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)9
        • 12.3.8.3.7 India: CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)0
      • 12.3.8.4 South Korea: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.3.8.4.1 Overview1
        • 12.3.8.4.2 South Korea: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.3.8.4.3 South Korea: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)2
        • 12.3.8.4.4 South Korea: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)2
        • 12.3.8.4.5 South Korea: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)2
        • 12.3.8.4.5.1 South Korea: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)3
        • 12.3.8.4.5.2 South Korea: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)3
        • 12.3.8.4.6 South Korea: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)3
        • 12.3.8.4.7 South Korea: CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)4
      • 12.3.8.5 Australia: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.3.8.5.1 Overview5
        • 12.3.8.5.2 Australia: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.3.8.5.3 Australia: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)6
        • 12.3.8.5.4 Australia: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)6
        • 12.3.8.5.5 Australia: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)6
        • 12.3.8.5.5.1 Australia: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)7
        • 12.3.8.5.5.2 Australia: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)7
        • 12.3.8.5.6 Australia: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)7
        • 12.3.8.5.7 Australia: CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)8
      • 12.3.8.6 Rest of Asia Pacific: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.3.8.6.1 Overview9
        • 12.3.8.6.2 Rest of Asia Pacific: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.3.8.6.3 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)0
        • 12.3.8.6.4 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by High-Risk HPV Strain, 2019-2028 (US$ Million)0
        • 12.3.8.6.5 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)0
        • 12.3.8.6.5.1 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)1
        • 12.3.8.6.5.2 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)1
        • 12.3.8.6.6 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)1
        • 12.3.8.6.7 Rest of Asia Pacific: CIN & HR-HPV Treatment Market, by End User, 2019-2028 (US$ Million)2
  • 12.4 Middle East & Africa CIN & HR-HPV Treatment Market 3
    • 12.4.1 Overview3
    • 12.4.2 Middle East & Africa: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)4
    • 12.4.3 Middle East & Africa: CIN & HR-HPV Treatment Market , by Disease Type, 2019-2028 (US$ Million)4
    • 12.4.4 Middle East & Africa: CIN & HR-HPV Treatment Market , by Strain Type, 2019-2028 (US$ Million)5
    • 12.4.5 Middle East & Africa: CIN & HR-HPV Treatment Market , by Offering, 2019-2028 (US$ Million)5
      • 12.4.5.1 Middle East & Africa: CIN & HR-HPV Treatment Market , by Diagnostic Methods, 2019-2028 (US$ Million)5
      • 12.4.5.2 Middle East & Africa: CIN & HR-HPV Treatment Market , by Treatment, 2019-2028 (US$ Million)6
    • 12.4.6 Middle East & Africa: CIN & HR-HPV Treatment Market , by Product Type, 2019-2028 (US$ Million)6
    • 12.4.7 Middle East & Africa CIN & HR-HPV Treatment Market , by End User, 2019-2028 (US$ Million)6
    • 12.4.8 Middle East & Africa: CIN & HR-HPV Treatment Market , by Country, 2022 & 2028 (%)7
      • 12.4.8.1 UAE: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.4.8.1.1 Overview7
        • 12.4.8.1.2 UAE: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.4.8.1.3 UAE: CIN & HR-HPV Treatment Market , by Disease Type, 2019-2028 (US$ Million)8
        • 12.4.8.1.4 UAE: CIN & HR-HPV Treatment Market , by Strain Type, 2019-2028 (US$ Million)8
        • 12.4.8.1.5 UAE: CIN & HR-HPV Treatment Market , by Offering, 2019-2028 (US$ Million)8
        • 12.4.8.1.5.1 UAE: CIN & HR-HPV Treatment Market , by Diagnostic Method, 2019-2028 (US$ Million)9
        • 12.4.8.1.5.2 UAE: CIN & HR-HPV Treatment Market , by Treatment, 2019-2028 (US$ Million)9
        • 12.4.8.1.6 UAE: CIN & HR-HPV Treatment Market , by Product Type, 2019-2028 (US$ Million)9
        • 12.4.8.1.7 UAE CIN & HR-HPV Treatment Market , by End User, 2019-2028 (US$ Million)0
      • 12.4.8.2 Saudi Arabia: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.4.8.2.1 Overview1
        • 12.4.8.2.2 Saudi Arabia: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.4.8.2.3 Saudi Arabia: CIN & HR-HPV Treatment Market , by Disease Type, 2019-2028 (US$ Million)2
        • 12.4.8.2.4 Saudi Arabia: CIN & HR-HPV Treatment Market , by Strain Type, 2019-2028 (US$ Million)2
        • 12.4.8.2.5 Saudi Arabia: CIN & HR-HPV Treatment Market , by Offerings, 2019-2028 (US$ Million)3
        • 12.4.8.2.5.1 Saudi Arabia: CIN & HR-HPV Treatment Market , by Diagnostic Methods, 2019-2028 (US$ Million)3
        • 12.4.8.2.5.2 Saudi Arabia: CIN & HR-HPV Treatment Market , by Treatment, 2019-2028 (US$ Million)3
        • 12.4.8.2.6 Saudi Arabia: CIN & HR-HPV Treatment Market , by Product Type, 2019-2028 (US$ Million)4
        • 12.4.8.2.7 Saudi Arabia CIN & HR-HPV Treatment Market , by End User, 2019-2028 (US$ Million)4
      • 12.4.8.3 South Africa: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.4.8.3.1 Overview5
        • 12.4.8.3.2 South Africa: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.4.8.3.3 South Africa: CIN & HR-HPV Treatment Market , by Disease Type, 2019-2028 (US$ Million)6
        • 12.4.8.3.4 South Africa: CIN & HR-HPV Treatment Market , by Strain Type, 2019-2028 (US$ Million)6
        • 12.4.8.3.5 South Africa: CIN & HR-HPV Treatment Market , by Offering, 2019-2028 (US$ Million)6
        • 12.4.8.3.5.1 South Africa: CIN & HR-HPV Treatment Market , by Diagnostic Method, 2019-2028 (US$ Million)7
        • 12.4.8.3.5.2 South Africa: CIN & HR-HPV Treatment Market , by Treatment, 2019-2028 (US$ Million)7
        • 12.4.8.3.6 South Africa: CIN & HR-HPV Treatment Market , by Product Type, 2019-2028 (US$ Million)7
        • 12.4.8.3.7 South Africa CIN & HR-HPV Treatment Market , by End User, 2019-2028 (US$ Million)8
      • 12.4.8.4 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.4.8.4.1 Overview9
        • 12.4.8.4.2 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)9
        • 12.4.8.4.3 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market , by Disease Type, 2019-2028 (US$ Million)0
        • 12.4.8.4.4 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market , by Strain Type, 2019-2028 (US$ Million)0
        • 12.4.8.4.5 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market , by Offering, 2019-2028 (US$ Million)0
        • 12.4.8.4.5.1 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market , by Diagnostic Method 2019-2028 (US$ Million)1
        • 12.4.8.4.5.2 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market , by Treatment, 2019-2028 (US$ Million)1
        • 12.4.8.4.6 Rest of Middle East & Africa: CIN & HR-HPV Treatment Market , by Product Type, 2019-2028 (US$ Million)2
        • 12.4.8.4.7 Rest of Middle East & Africa CIN & HR-HPV Treatment Market , by End User, 2019-2028 (US$ Million)2
  • 12.5 South and Central America CIN & HR-HPV Treatment Market 3
    • 12.5.1 Overview3
    • 12.5.2 South and Central America CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)3
    • 12.5.3 South and Central America: CIN and HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)4
    • 12.5.4 South and Central America: CIN and HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)4
    • 12.5.5 South and Central America: CIN and HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)5
      • 12.5.5.1 South and Central America: CIN and HR-HPV Treatment Market, by Diagnostic Method, 2019-2028 (US$ Million)5
      • 12.5.5.2 South and Central America: CIN and HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)6
    • 12.5.6 South and Central America: CIN and HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)6
    • 12.5.7 South and Central America: CIN and HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)6
      • 12.5.7.1 Argentina: CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)7
        • 12.5.7.1.1 Overview7
        • 12.5.7.1.2 Argentina CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)8
        • 12.5.7.1.3 Argentina CIN and HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)8
        • 12.5.7.1.4 Argentina CIN and HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)9
        • 12.5.7.1.5 Argentina CIN and HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)9
        • 12.5.7.1.5.1 Argentina: CIN and HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)9
        • 12.5.7.1.5.2 Argentina: CIN and HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)0
        • 12.5.7.1.6 Argentina CIN and HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)0
        • 12.5.7.1.7 Argentina CIN and HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)0
      • 12.5.7.2 Brazil: CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.5.7.2.1 Overview1
        • 12.5.7.2.2 Brazil CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)1
        • 12.5.7.2.3 Brazil CIN and HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)2
        • 12.5.7.2.4 Brazil CIN and HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)2
        • 12.5.7.2.5 Brazil CIN and HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)2
        • 12.5.7.2.5.1 Brazil: CIN and HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)3
        • 12.5.7.2.5.2 Brazil: CIN and HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)3
        • 12.5.7.2.6 Brazil CIN and HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)3
        • 12.5.7.2.7 Brazil CIN and HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)4
      • 12.5.7.3 Rest of South and Central America: CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.5.7.3.1 Overview5
        • 12.5.7.3.2 Rest of South and Central America CIN and HR-HPV Treatment Market - Revenue and Forecast to 2028 (US$ Million)5
        • 12.5.7.3.3 Rest of South and Central America CIN and HR-HPV Treatment Market, by Disease Type, 2019-2028 (US$ Million)6
        • 12.5.7.3.4 Rest of South and Central America CIN and HR-HPV Treatment Market, by Strain Type, 2019-2028 (US$ Million)6
        • 12.5.7.3.5 Rest of South and Central America CIN and HR-HPV Treatment Market, by Offerings, 2019-2028 (US$ Million)6
        • 12.5.7.3.5.1 Rest of South and Central America: CIN and HR-HPV Treatment Market, by Diagnostic Methods, 2019-2028 (US$ Million)7
        • 12.5.7.3.5.2 Rest of South and Central America: CIN and HR-HPV Treatment Market, by Treatments, 2019-2028 (US$ Million)7
        • 12.5.7.3.6 Rest of South and Central America CIN and HR-HPV Treatment Market, by Product Type, 2019-2028 (US$ Million)8
        • 12.5.7.3.7 Rest of South and Central America CIN and HR-HPV Treatment Market, by End Users, 2019-2028 (US$ Million)8

13. Impact Of COVID-19 Pandemic on CIN & HR-HPV Treatment Market 9

  • 13.1 North America: Impact Assessment of COVID-19 Pandemic9
  • 13.2 Europe: Impact Assessment of COVID-19 Pandemic1
  • 13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic3
  • 13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic5
  • 13.5 Impact Analysis of COVID-19 Pandemic on South and Central America CIN and HR-HPV Treatment Market6

14. CIN & HR-HPV Treatment Market - Industry Landscape8

  • 14.1 Overview8
  • 14.2 Growth Strategies in CIN & HR-HPV Treatment Market8
  • 14.3 Organic Growth Strategies9
    • 14.3.1 Overview9
  • 14.4 Inorganic Growth Strategies0
    • 14.4.1 Overview0

15. Company Profiles1

  • 15.1 Fujirebio Europe NV1
    • 15.1.1 Key Facts1
    • 15.1.2 Business Description1
    • 15.1.3 Products and Services1
    • 15.1.4 Financial Overview2
    • 15.1.5 SWOT Analysis2
    • 15.1.6 .Key Developments2
  • 15.2 Qiagen NV3
    • 15.2.1 Key Facts3
    • 15.2.2 Business Description3
    • 15.2.3 Products and Services3
    • 15.2.4 Financial Overview4
    • 15.2.5 SWOT Analysis6
    • 15.2.6 Key Developments7
  • 15.3 Zilico Ltd8
    • 15.3.1 Key Facts8
    • 15.3.2 Business Description8
    • 15.3.3 Products and Services8
    • 15.3.4 Financial Overview8
    • 15.3.5 SWOT Analysis9
    • 15.3.6 Key Developments9
  • 15.4 Abbott Laboratories0
    • 15.4.1 Key Facts0
    • 15.4.2 Business Description0
    • 15.4.3 Products and Services0
    • 15.4.4 Financial Overview1
    • 15.4.5 SWOT Analysis2
    • 15.4.6 Key Developments2
  • 15.5 Cepheid3
    • 15.5.1 Key Facts3
    • 15.5.2 Business Description3
    • 15.5.3 Products and Services3
    • 15.5.4 Financial Overview3
    • 15.5.5 SWOT Analysis4
    • 15.5.6 Key Developments4
  • 15.6 F. Hoffmann-La Roche Ltd5
    • 15.6.1 Key Facts5
    • 15.6.2 Business Description5
    • 15.6.3 Products and Services6
    • 15.6.4 Financial Overview6
    • 15.6.5 SWOT Analysis8
    • 15.6.6 Key Developments8
  • 15.7 INOVIO Pharmaceuticals Inc0
    • 15.7.1 Key Facts0
    • 15.7.2 Business Description0
    • 15.7.3 Products and Services0
    • 15.7.4 Financial Overview1
    • 15.7.5 SWOT Analysis2
    • 15.7.6 Key Developments2
  • 15.8 Bioneer Corp4
    • 15.8.1 Key Facts4
    • 15.8.2 Business Description4
    • 15.8.3 Products and Services4
    • 15.8.4 Financial Overview5
    • 15.8.5 SWOT Analysis6
    • 15.8.6 Key Developments6
  • 15.9 Antiva Biosciences Inc7
    • 15.9.1 Key Facts7
    • 15.9.2 Business Description7
    • 15.9.3 Products and Services7
    • 15.9.4 Financial Overview7
    • 15.9.5 SWOT Analysis8
    • 15.9.6 Key Developments8
  • 15.10 Thermo Fisher Scientific Inc9
    • 15.10.1 Key Facts9
    • 15.10.2 Business Descri
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제